References
- Wooldridge M. Address at the Annual General. Meeting of the Royal Australasian College of Physicians Scientific Meeting, Canberra, 8 May, 1996
- Zanchetti A. Lacidipine—A clinical monograph. Adis, ChesterU.K. 1994; 1–60
- Bond MG, Mercuri M. for the ELSA Research Group. Potential modification of plaque behavior through the European Lacidipine Study on Atherosclerosis. J Cardiovasc Pharmacol 1995; 25: S1–6
- Dahlöf B, Hansson L, Lindholm LH. STOP Hypertension-2: a prospective intervention trial of “newer” versus “older” treatment alternatives in old patients with hypertension. Blood Pressure 1993; 2: 36
- The NORDIL Group. The Nordic Diltiazem Study (NORDIL). A prospective intervention trial of calcium antagonist therapy in hypertension. Blood Pressure 1993; 2: 312–21
- Davis BR, Cutler JA, Gordon DJ. Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). Am J Hypertens 1996; 9: 342–60
- Psaty BM, Heckbert SR, Koepsell TD, Siscovic DS, Raghuanathan TE, Weiss NS. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620–5
- Buring JE, Glynn RJ, Hennekens CH. Calcium channel blockers and myocardial infarction. A hypothesis formulated but not yet tested. JAMA 1995; 274: 654–5
- Lenfant C. The calcium channel blocker scare. Lessons for the future. Circulation 1995; 91: 2855–6
- Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326–31
- Horton R. Spinning the risks and benefits of calcium antagonists. Lancet 1995; 346: 586
- Pahor M, Guralnik JM, Corti M, Foley DJ, Carboni P, Havlik RJ. Long-term survival and use of antihypertensive medication in older persons. J Am Ger Soc 1995; 43: 1–7
- Mancia G, van Zwieten P. How safe are calcium antagonists in hypertension and coronary heart disease?. J Hypertens 1996; 14: 13–7
- Meyer H. Structure-activity relationship in calcium antagonists. In: Opie LH, ed. Perspectives in cardiovascular pharmacology. New York: Ravern Press 1984; 9: 165–73
- Herbette LG, Gaviraghi G, Tulenko T, Mason RP. Molecular interaction between lacidipine and biological membranes. J Hypertens 1993; 11: S13–9
- European Commission Committee for Proprietary Medical Products. Guidelines for the clinical investigation of medical products in the treatment of hypertension. European Commission, Brussels 1994
- Yusuf S. Calcium antagonists in coronary artery disease and hypertension. Time for revaluation? (Editorial) Circulation 1995; 92: 1079–82
- Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA. Blood pressure, stroke and coronary heart disease. Part 2, short term reductions in blood pressure: overview of randomised trials in their epidemiological context. Lancet 1990; 335: 827–38
- Aursnes I, Litleskare I, Froyland H, Abdelnoor M. Association between various drugs used for hypertension and risk of acute myocardial infarction. Blood Pressure 1995; 4: 157–63
- Cutler J, Psaty BM, MacMahon S, Furberg CD. Public health issues in hypertension control: What has been learned from clinical trials. Hypertension: pathophysiology, diagnosis, and management 2nd edn, JH Laragh, BM. Brenner. Raven Press, New York 1995; 253–70
- Dahlof B, Lindholm L, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hyper-tension). Lancet 1991; 338: 1281–5
- Heber ME, Broadhurst PA, Bridgen GS, Raftery EB. Effectiveness of the once-daily calcium antagonist, lacidipine, in controlling 24-hour ambulatory blood pressure. Am J Cardiol 1990; 66: 1228–32
- Meredith PA, Reid JL. Differences between calcium antagonists: duration of action and trough to peak ratio. J Hypertens 1993; 11: S21–6
- Heber ME, Broadhurst PA, Brigden GS, Raftery EB. Effectiveness of the once-daily calcium antagonist, lacidipine, in controlling 24-hour ambulatory blood pressure. Am J Cardiol 1990; 66: 1228–32
- Rizzini P, Castello C, Salvi S, Recchia G. Efficacy and safety of lacidipine, a new long-lasting calcium antagonist, in elderly hypertensive patients. J Cardiovasc Pharmacol 1991; 17: S38–44